ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative
RNS Number : 2348I MaxCyte, Inc. 15 October 2024 MaxCyte Appoints Cynthia Collins to its Board of Directors Rockville, MD , Oct. 15, 2024 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative
RNS Number : 8857H MaxCyte, Inc. 11 October 2024 MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 ROCKVILLE, MD , October 11, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT ), a leading, cell-engineering focused company providing enabling platform technologies to
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative
RNS Number : 7240H MaxCyte, Inc. 10 October 2024 MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer Rockville, MD , Oct. 10, 2024 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance
RNS Number : 8297G MaxCyte, Inc. 03 October 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , October 3, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 4478G MaxCyte, Inc. 01 October 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , October 1, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 3118G MaxCyte, Inc. 01 October 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , October 1, 2024 : MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 0893G MaxCyte, Inc. 27 September 2024 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
